Persantine - Dipyridamole

Short-acting dipyridamole (Persantine). Do not consider the long-acting dipyridamole (which has better properties than the short-acting in older adults) except with patients with artificial heart valves May cause orthostatic hypotension Low... 

Dipyridamole (Persantine) is a vasodilator that, in combination with warfarin, inhibits embolization from prosthetic heart valves and, in combination with aspirin, reduces thrombosis in patients with thrombotic diseases. Dipyridamole by itself has little or no benefit in fact, in trials where a regimen of dipyridamole plus aspirin was compared with aspirin alone, dipyridamole provided no additional beneficial effect. Dipyridamole interferes with platelet function by increasing the cellular concentration of adenosine 3, 5 -monophosphate (cyclic AMP). This effect is mediated by inhibition of cyclic nucleotide phosphodiesterase and by blockade of uptake of adenosine, which acts at A2 receptors for adenosine to stimulate platelet adenylyl cyclase. The only current recommended use of dipyridamole is for primary prophylaxis of thromboemboli in patients with prosthetic heart valves the drug is given in combination with warfarin. 

Parenteral 750 anti-Xa units/vial Dipyridamole (Persantine)... 

Barary et al. used a derivative spectrophotometric method for the determination of dipyridamole and carbocromen hydrochloride in the presence of their oxidative degradation products [26], Dipyridamole in 0.1 M hydrochloric acid was determined by first derivative (Di) spectrophotometry at 240 and 260 nm, and by second derivative (D2) spectrophotometry at 246 and 268 nm. For both drugs, 0.1 M-hydrochloric acid was used as a blank. Graphs of Di and D2 were linear for 4-12pg/mL of dipyridamole. The technique effectively corrects for the presence of degradation products. This method was used successfully to determine dipyridamole in persantin tablets. 

Nie et al. used a flow injection chemiluminescence method for the determination of dipyridamole in Persantin tablets [51]. A flow injection analysis system equipped with a chemiluminescence detector was used. Sodium hypochlorite was used as a chemiluminescent substance, and Triton X-100 was used as an enhancer of the chemiluminescence reaction. Sample solutions (pH 4-6) was injected into 0.2% Triton X-100 and treated with 0.5% sodium hypochlorite, and the chemiluminescence intensity then measured. The calibration graph was linear from 0.04 to 10 pg/mL of Persantin tablets (as its active ingredient dipyridamole), with a detection limit of 11 ng/mL. Recoveries were quantitative and the relative standard deviation ( = 3) was 2.7%. The method has been used to determine Persantin in injection and tablets, and the results obtained using this method agreed with those obtained by the Chinese Pharmacopoeial method. 

Picano E PISA (Persantin In Stable Angina) study group. Dipyridamole in chronic stable angina pectoris a randomized, double blind, placebo-controlled, parallel group study. Eur Heart J 2001 22(19) 1785-93. 

Dipyridamole. Dipyridamole. 2.2. 2".2" -l(4.8-di-l-piperidinylpyrimido 5.4-dIpyrimidine-2.6-diyl)dinitrilol-Icuakisethanol (Persantine), may be used for coronaiy and myocardial insufficiency. Its biggest use today, however. is a.s an antithrombotic in patients with prosthetic heart valves. It is a bitter, yellow, crystalline powder, soluble in dilute acids, methanol, or chloroform. A formulation containing dipyridamole and aspirin (Aggrenox) is currently being marketed as an antithromobotic. 

Diprosone betamethasone. diprOtin A is a tripeptide that is an ENZYME INHIBITOR with selectivity as an aminopeptidase inhibitor active against dipeptidylpeptidase IV (EC 3.4.11). It can be used as a pharmacological tool in experimental analytical studies, dipyridamole [ban, inn, usan] (Persantin ) is a pyrimidine derivative, a coronary VASODILATOR, a (class la) ANTIARRHYTHMIC, an adenosine UPTAKE INHIBITOR causing indirect adenosine receptor activation, and enhances effects of anticoagulants and is a platelet AGGREGATION INHIBITOR. 

Dipyridamole (Persantine) evolved from a synthetic study of pyrimido (5,4-d) pyrimidines as a coronary vasodilator over three decades ago. Some early studies indicated that the increased coronary flow alleviated ischemic 02 demand and was therefore useful prophy-lactically in angina. With the advent of well-controlled as well as long-term studies in more recent years, it became apparent that the drug cannot be convincingly shown to have the efficacy it was believed by some to have—this in spite of the fact that it does dilate coronary resistance vessels, but not the conductance vessels the nitrates dilate. 

---